**MONDAY, AUGUST 17**

**Keynote Address**

James P. Allison, University of Texas MD Anderson Cancer Center, USA
*Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms*

**Mechanisms of Action I**

*Ira Mellman*, Genentech, Inc., USA
*Mechanistic Basis of Cancer Immunotherapy*

*Kelli Connolly*, Yale University, USA
*Short Talk: Tumor-Draining Lymph Nodes Contain an Untapped Reservoir of Stem-Like CD8 T Cells*

*Ahyun Choi*, Novartis Institutes for BioMedical Research, USA
*Short Talk: Loss of EMTC Inhibits Tumor Growth through Enhanced Adaptive Immune Response*

**Mechanisms of Action II**

*Jane Oliaro*, Peter MacCallum Cancer Centre, Australia
*Identifying New Targets for Cancer Immunotherapy*

*Vandana Kalia*, University of Washington and Seattle Children’s Research Institute, USA
*Short Talk: PD-1 Signals Are Critical for Maintenance of CD8 T Cell Memory*

*Katie Campbell*, University of California, Los Angeles, USA
*Short Talk: Integrating DNA and RNA Sequencing Analyses to Describe Somatic Alterations and Expression in the HLA Gene Loci*

*Stephen Mok*, MD Anderson Cancer Center, USA
*Short Talk: Late Interferon-Gamma Blockade Improves Antitumor Efficacy of Anti-CTLA-4 and Anti-PD-1 Combination Treatment*

**Mechanisms of Response I**

*Siwen Hu-Lieskovsk*, Huntsman Cancer Institute, USA
*Clinical Testing Strategies against Heterogenous Mechanisms of Immune Resistance*

*Antoni Ribas*, University of California, Los Angeles, USA
*Mechanisms of Primary and Acquired Resistance to PD-1 Blockade Therapy*

*Chang Liu*, University of Pittsburgh, USA
*Short Talk: Neuropilin-1 Is a T Cell Memory Checkpoint Limiting Long-Term Anti-Tumor Immunity*

**Mechanisms of Response II**

*Padmanee Sharma*, University of Texas MD Anderson Cancer Center, USA
*From the Clinic to the Lab: Investigating Mechanisms of Response and Resistance to Immune Checkpoint Therapy*

*Yuxuan Miao*, Rockefeller University, USA
*Short Talk: Adaptive Immune Resistance Emerges From Tumor-Initiating Stem Cells*

**Poster Session**

**TUESDAY, AUGUST 18**

**Therapeutic Play I**

*Yvonne Y. Chen*, University of California, Los Angeles, USA
*Engineering Next-Generation CAR-T Cell Therapy for Cancer*

*Juan C. Jaen*, Arcus Biosciences, Inc., USA
*Clinical Applications of Adenosine Pathway Inhibitors*

*Coralie Backlund*, Massachusetts Institute of Technology, USA
*Short Talk: Cell Penetrating Peptides Improve T Cell Response to Neoantigen Peptide Vaccines*

*Maija Hollmén*, University of Turku, Finland
*Short Talk: Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumours*

* Yingxiao Wang*, University of California, San Diego, USA
*Short Talk: Engineering Remotely Controllable CAR T Cells for Cancer Immunotherapy*

**Therapeutic Play II**

*Evans Scott*, Northwestern University, USA
*Engineered Nanobiomaterials for Cancer Immunotherapy*

*E. John Wherry*, University of Pennsylvania, USA
*Epigenetic Features of Exhausted Antitumor T Cells*

*Buvana Ravishankar*, Rapt Therapeutics, Inc., USA
*Short Talk: Targeting the Stress Response Kinase GCN2 Potentiates Anti-Tumor Immune Response*

*Anthony K. Park*, City of Hope, USA
*Short Talk: Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumours*

*Patrick A. Ott*, Dana-Farber Cancer Institute, USA
*Short Talk: Personal Neoantigen Vaccines Induce Long-term Immune Responses in Patients with High Risk Melanoma*

**Meet-the-Editors Roundtable**

*Alessandra Fornarelli*, Frontiers, Switzerland

*Paloma Portela Torres*, SAGE Publications Ltd, UK

*Lise Roth*, European Molecular Biology Organization, Germany

**Genomics of Cancer I**

*Priti Hegde*, Foundation Medicine, USA
*Pan-Cancer Analysis of Allele-Specific HLA-I Loss Suggests Widespread Occurrence across a Diverse Range of Tumor Types*

*Eliezer M. Van Allen*, Dana-Farber Cancer Institute, USA
*Tumor Genomics and Selective Response to Cancer Immunotherapy*
Nadine A. Defranoux, Parker Institute for Cancer Immunotherapy, USA
Short Talk: Strategies to Improve the Sensitivity and Ranking Ability of Neoantigen Prediction Methods: Report on the Results of the Tumor nEoantigen SeLection Alliance (TESLA)

Gloria Bora Kim, University of Pennsylvania, USA
Short Talk: Splice Variants as Neoantigens for Cancer Immunotherapy

Genomics of Cancer II
Elaine R. Mardis, Nationwide Children's Hospital, USA
Immunogenomics and the TME in Pediatric CNS Cancers

Thomas D. Wu, Genentech, Inc., USA
Short Talk: Peripheral T Cell Expansion Predicts Tumor Infiltration and Clinical Response to Cancer Immunotherapy

Debattama Sen, Harvard Medical School, USA
Short Talk: Disrupting Enhancers within the Core Epigenetic Program of Exhaustion Improves CD8+ T Cell Responses and Enhances Tumor Control

WEDNESDAY, AUGUST 19

Single Cell I
James R. Heath, Institute for Systems Biology, USA
Single Cell Approaches to Analyzing Antitumor Responses

*Ansuman Satpathy, Stanford University School of Medicine, USA
Single-Cell Genomics in Cancer Immunotherapy

Christine Carine Moussion, Genentech, Inc., USA
Short Talk: Local Heterogeneity of Response to CIT: Learning from the STAMP Live Imaging Model

James C. Lee, University of California, San Francisco, USA
Short Talk: Liver Metastasis Mediated Control of Systemic Tumor-Specific Immunity and Response to Checkpoint Immunotherapy

Single Cell II
*Sohail F. Tavazoie, Rockefeller University, USA
Depleting Myeloid-Suppressive Cells for Cancer Immunotherapy

Theodore Roth, University of California, San Francisco, USA
Short Talk: Parallel Engineering of Immune Cell Genomes by Pooled Knockin Targeting

Amanda Oliver, Peter MacCallum Cancer Centre, Australia
Short Talk: Tissue-Specific Tumour Microenvironments Influence Responses to Immunotherapy